↓ Skip to main content

Dove Medical Press

Immature platelets and antiplatelet therapy response to aspirin in Kawasaki disease

Overview of attention for article published in Drug Design, Development and Therapy, May 2018
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
21 Mendeley
Title
Immature platelets and antiplatelet therapy response to aspirin in Kawasaki disease
Published in
Drug Design, Development and Therapy, May 2018
DOI 10.2147/dddt.s163705
Pubmed ID
Authors

Lei Pi, Di Che, Haifeng Long, Zhenzhen Fang, Jiawen Li, Shuyi Lin, Yunfeng Liu, Meiai Li, Lijuan Bao, Wenli Li, Yuan Zhang, Qiulian Deng, Techang Liu, Li Zhang, Xiaoqiong Gu

Abstract

Kawasaki disease is a kind of systemic vasculitis that mainly damages moderate and small-sized blood vessels, and is a leading cause of coronary artery lesions (CAL). Antiplatelet therapy is a routine component of Kawasaki disease treatment strategies. So it is important to evaluate the antiplatelet effect of aspirin because of the individual biological variability of antiplatelet effect of aspirin. The immature platelet fraction (IPF) has attracted particular attention as it may influence the antiplatelet effect of aspirin. This study investigated the prognostic factors for evaluating the degree of vasculitis and the effect of antiplatelet therapy in children with Kawasaki disease. Blood samples were collected from 44 patients with Kawasaki disease before aspirin treatment and 7 to 10 days after treatment. The IPF counts, percentage of the IPF, and highly fluorescent IPF were detected by a Sysmex XE-5000 instrument. The levels of 11-dehydrothromboxane B2 (11-DH-TXB2), soluble CD40 ligand (sCD40L), and soluble P-selectin (sP-selectin) were measured by ELISA. The correlation between the measured factors and the degree of coronary artery damage in Kawasaki disease was analyzed. We found that 11-DH-TXB2, sP-selectin, and sCD40L levels were much more elevated in the CAL group than in the non-coronary artery lesions (NCAL) group before aspirin treatment. The concentrations of 11-DH-TXB2, sCD40L, sP-selectin, and IPF were reduced after aspirin treatment in the NCAL group but not the CAL group. This is related to the degree of coronary artery damage in Kawasaki disease patients. Additionally, 11-DH-TXB2, sCD40L, sP-selectin, and IPF were positively correlated with the degree of coronary artery damage in Kawasaki disease patients. The current study suggests that the presence of high plasma concentrations of 11-DH-TXB2, sCD40L, sP-selectin, and IPF can be considered a risk factor and experimental biomarker for CAL in Kawasaki disease patients.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 21 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 3 14%
Professor 2 10%
Researcher 2 10%
Librarian 1 5%
Student > Bachelor 1 5%
Other 4 19%
Unknown 8 38%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 14%
Medicine and Dentistry 3 14%
Nursing and Health Professions 2 10%
Agricultural and Biological Sciences 2 10%
Psychology 1 5%
Other 2 10%
Unknown 8 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 June 2018.
All research outputs
#22,767,715
of 25,382,440 outputs
Outputs from Drug Design, Development and Therapy
#1,753
of 2,268 outputs
Outputs of similar age
#298,886
of 339,234 outputs
Outputs of similar age from Drug Design, Development and Therapy
#48
of 58 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 339,234 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.